FACS Aria II for Flow Cytometry Core Facility

用于流式细胞术核心设施的 FACS Aria II

• 批准号: 7794292
• 负责人: Teresa Liberati
• 金额: $ 47.29万
• 依托单位: SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-15 至 2011-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7794292
• 关键词: Area; Cell Separation; Cells; Collection; Communicable Diseases; Core Facility; Data Collection; Development; Faculty; Flow Cytometry; Funding; Grant; Illinois; Investments; Malignant Neoplasms; National Center for Research Resources; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Disease; Pathologic Processes; Population; Population Heterogeneity; Process; Productivity; Research; Research Personnel; Resolution; Sorting - Cell Movement; Source; System; Technology; Therapeutic Effect; United States National Institutes of Health; Universities; Vendor; cell type; instrumentation; interest; medical schools; meetings; member; tool

DESCRIPTION (provided by applicant): The Southern Illinois University School of Medicine requests support to purchase a new flow cytometer for our core lab. The requested BD FACSAria II will replace a FACSVantage that was purchased with a Shared Instrumentation Grant in 1993 and remains in use today as our only cell sorter, documenting an incredible return-on-investment for NCRR. However, this unit is quite outdated and no longer meets the research needs of our faculty. Furthermore, after 2009 the Vantage will no longer be supported by the vendor. The FACSAria II will support a core of 7 NIH-funded faculty members with diverse research interests, as indicated by their varied sources of NIH funding (NCI, NHLBI, and NIAID). FACSAria II technology will effectively increase the quality of their data collection, their available research options, and their overall productivity. The ability to obtain high-quality populations of sorted cells will contribute to more rapid advances in our understanding of the causes and course of cancer, infectious diseases, cell development, and other aspects of cellular and biomolecular processes. Because the FACSAria II allows rapid, reliable cell sorting, it reduces the cell loss and variability inherent in older systems. By increasing the temporal and spatial resolution of the sorting, the technology allows collection of specific but rare cell types from a heterogeneous population, thereby supporting precise and accurate characterization of therapeutic effects and normal versus pathological processes. These benefits will allow our NIH- funded and other investigators to advance their respective research areas in ways not otherwise possible with the tools currently available to them at SIUSM.

描述（由申请人提供）：南伊利诺伊大学医学院请求支持为我们的核心实验室购买一台新的流式细胞仪。所要求的 BD FACSAria II 将取代 FACSVantage，该 FACSVantage 于 1993 年通过共享仪器补助金购买，至今仍作为我们唯一的细胞分选仪使用，为 NCRR 带来了令人难以置信的投资回报。然而，这个单位已经相当过时了，不再满足我们教师的研究需求。此外，2009 年之后，供应商将不再支持 Vantage。 FACSAria II 将支持 7 名 NIH 资助的核心教员，他们具有不同的研究兴趣，这从他们获得 NIH 资助的不同来源（NCI、NHLBI 和 NIAID）就可以看出。 FACSAria II 技术将有效提高数据收集的质量、可用的研究选项以及整体生产力。获得高质量分选细胞群的能力将有助于我们对癌症、传染病、细胞发育以及细胞和生物分子过程的其他方面的原因和病程的理解更快地取得进展。由于 FACSAria II 可以进行快速、可靠的细胞分选，因此可以减少旧系统中固有的细胞损失和变异性。通过提高分选的时间和空间分辨率，该技术可以从异质群体中收集特定但稀有的细胞类型，从而支持治疗效果以及正常与病理过程的精确表征。这些好处将使我们的 NIH 资助的研究人员和其他研究人员能够以 SIUSM 目前可用的工具无法实现的方式推进各自的研究领域。

项目成果

Data in support of transcriptional regulation and function of Fas-antisense long noncoding RNA during human erythropoiesis.

支持人类红细胞生成过程中 Fas 反义长非编码 RNA 的转录调控和功能的数据。

• DOI: 10.1016/j.dib.2016.03.106
• 发表时间: 2016
• 期刊: Data in brief
• 影响因子: 1.2
• 作者: Villamizar,Olga;Chambers,ChristopherB;Mo,Yin-Yuan;Torry,DonaldS;Hofstrand,Reese;Riberdy,JaniceM;Persons,DerekA;Wilber,Andrew
• 通讯作者: Wilber,Andrew

A system for creating stable cell lines that express a gene of interest from a bidirectional and regulatable herpes simplex virus type 1 promoter.

• DOI: 10.1371/journal.pone.0122253
• 发表时间: 2015
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Chambers CB;Halford WP;Geltz J;Villamizar O;Gross J;Embalabala A;Gershburg E;Wilber A
• 通讯作者: Wilber A

Fas-antisense long noncoding RNA is differentially expressed during maturation of human erythrocytes and confers resistance to Fas-mediated cell death.

• DOI: 10.1016/j.bcmd.2016.03.002
• 发表时间: 2016-05
• 期刊: Blood cells, molecules & diseases
• 作者: Olga Villamizar;C. Chambers;Y. Mo;D. Torry;R. Hofstrand;J. Riberdy;D. Persons;A. Wilber

Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis.

• DOI: 10.18632/oncotarget.7329
• 发表时间: 2016-03-22
• 期刊: Oncotarget
• 作者: Villamizar O;Chambers CB;Riberdy JM;Persons DA;Wilber A
• 通讯作者: Wilber A